GTA-Glyceryltriacetate for Canavan Disease
Recruitment status was: Active, not recruiting
|Infantile Canavan Disease Deficiency Disease, Aspartoacylase||Drug: GTA: Glyceryltriacetate||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 1 Treatment With GTA in Two Infant With Canavan Disease|
- All primary outcome will be evaluated 4 months following the initiation of treatment:
- Neurological Status
- Brain Imaging: MRI & MRS
- NAA Levels in Urine
- Ophthalmologic Examination
|Study Start Date:||January 2006|
|Estimated Study Completion Date:||July 2006|
Canavan Disease is caused by a deficiency in the enzyme named Aspartoacylase (ASPA). This disease is a devastating, progressive disease with no available treatment. As a result of the ASPA deficiency, there are high levels of N-acetylaspartate (NAA) and low levels of L-aspartate and acetate.
We hypothesize that one of the functions of ASPA is to provide sufficient levels of acetate for CNS myelinization. For this reason, we offer to supplement acetate levels by the oral administration of glyceryl triacetate (GTA). Such treatment must be offered to patients before the age of 18 months, prior to the termination of CNS myelinization.
- Two patients, aged less than 15 months, will receive daily doses of oral GTA
- The daily dose will be increased incrementally until the maintenance dose is reached. This will be done under close monitoring of the patients, including periodic blood gas sampling.
- GTA has not been shown to cause any known toxicity, according to the Cosmetic Ingredient Review Expert Panel (Fiume, 2003).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00278707
|Dr. Y. Anikster|
|Tel Aviv, Israel, 52621|
|Principal Investigator:||Yair Anikster, MD PI||Director Metabolic Disease Unit|